Core Insights - Pomerantz LLP is investigating claims on behalf of investors of The Greenbrier Companies, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - Greenbrier reported fiscal second quarter 2025 results, with non-GAAP earnings per share of $1.69, missing consensus estimates by $0.09, and revenues of $762.1 million, missing estimates by $136.43 million, reflecting a year-over-year decline of 11.7% [3] - Following the financial report, Greenbrier's stock price dropped by $5.11, or 11.42%, closing at $39.63 per share on April 8, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q2 2025 were reported at $1.69, which was $0.09 below consensus estimates [3] - Total revenues for the quarter were $762.1 million, missing consensus estimates by $136.43 million and showing an 11.7% decline year-over-year [3] Operational Changes - Greenbrier announced the closure of a facility in Romania, attributing the decision to market conditions and a comprehensive analysis in Europe [3]

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DuPont de Nemours, Inc. (“DuPont” or the “Company”) (NYSE: DD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether DuPont and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 4, 20 ...

Core Viewpoint - A class action lawsuit has been filed against Bakkt Holdings, Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by June 2, 2025 [2][3]. - The lawsuit pertains to Bakkt and its officers/directors' potential engagement in securities fraud [2]. Group 2: Revenue Impact - Bakkt disclosed that Webull Pay LLC will terminate its commercial agreement, which accounted for 74% of Bakkt's crypto services revenue in the nine months ending September 30, 2024 [4]. - The company derived 98% of its total revenue from crypto services during the same period [4]. - Additionally, Bank of America is terminating its loyalty services contract, which represented 17% of Bakkt's loyalty services revenue [4]. - These cancellations are projected to result in a 73% loss in top line revenue going forward [4]. Group 3: Stock Market Reaction - Following the announcement of these cancellations, Bakkt's stock price fell by $3.50 per share, a decrease of 27.28%, closing at $9.33 per share on March 18, 2025 [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Altria Group, Inc. and its executives, following a downgrade by Deutsche Bank due to regulatory uncertainties impacting the company's e-vapor products [1][3]. Group 1: Investigation and Legal Actions - Pomerantz LLP is conducting an investigation on behalf of Altria investors regarding possible securities fraud or other unlawful business practices by the company and its officers [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1]. Group 2: Stock Performance and Analyst Ratings - On April 2, 2025, Deutsche Bank downgraded Altria's stock rating from "Buy" to "Hold" due to regulatory uncertainties after a ruling by the U.S. International Trade Commission regarding patent infringement related to Altria's NJOY ACE e-vapor products [3]. - Following the downgrade, Altria's stock price decreased by $1.67, or 2.84%, closing at $57.12 per share on the same day [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Adverum Biotechnologies, Inc. following the company's announcement of the need to restate its financial statements due to accounting errors [1][2]. Group 1: Company Financials - On March 31, 2025, Adverum disclosed that certain previously issued financial statements should no longer be relied upon due to non-cash errors related to tenant improvement allowances for an operating lease in North Carolina [2]. - Adverum will restate its financial statements for the years ended December 31, 2022 and 2023, as well as the unaudited quarterly financial information for the periods in 2023 and 2024 [2]. - Following this announcement, Adverum's stock price fell by $0.54 per share, or 12.36%, closing at $3.83 per share on April 1, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]. - The firm has a track record of recovering multimillion-dollar damages for class members [3].

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Nyxoah S.A. and its officers or directors [1] Company Developments - On March 25, 2025, Nyxoah announced that the FDA issued an Approvable Letter for its Pre-Market Approval application for the Genio® system, indicating that the application substantially meets regulatory requirements [3] - The FDA's approval is contingent upon satisfactory completion of a review of manufacturing facilities, methods, and controls [3] - Following this announcement, analysts projected a delay in the commercial launch of the Genio system pending further FDA review [3] Market Reaction - Nyxoah's stock price fell by $2.42 per share, or 21.36%, closing at $8.91 per share on March 26, 2025, in response to the news [4]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Pony AI Inc. and its officers or directors [1] Group 1: Company Overview - Pony AI Inc. conducted its U.S. initial public offering (IPO) on November 27, 2024, offering 20 million American Depositary Shares (ADSs) at a price of $13.00 per share [3] - The company reported a significant decline in financial performance, with a 29.8% year-over-year decrease in sales and a 61.9% year-over-year decline in Robotaxi services revenue for the year ended December 31, 2024 [3] Group 2: Market Reaction - Following the announcement of its financial results, Pony's ADS price dropped by $1.07, or 8.1%, closing at $12.14 per ADS on March 25, 2025 [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Xponential Fitness, Inc. and its officers or directors following the company's disappointing financial results and subsequent stock price drop [1][3]. Financial Performance - On March 13, 2025, Xponential reported an unexpected loss for the fourth quarter and a 7.7% year-over-year revenue decline [3]. - The company's Board of Directors announced that the financial statements for the fiscal year ended December 31, 2023, would need to be restated [3]. - Following these announcements, Xponential's stock price fell by $4.66 per share, or 38.45%, closing at $7.46 per share on March 14, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of investors of Xponential Fitness, Inc. regarding possible securities fraud [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by KinderCare Learning Companies, Inc. and its officers or directors [1] Group 1: IPO and Financial Performance - KinderCare conducted its initial public offering on October 9, 2024, selling 24 million shares at $24.00 per share [2] - For the fourth quarter of 2024, KinderCare reported an operational loss of $89.3 million, a significant decline from an operational income of $48.7 million in the previous year, attributed to increased equity-based compensation expenses and lower COVID-19 stimulus reimbursements [3] - The full-year guidance provided by KinderCare fell short of consensus estimates [3] Group 2: Stock Price Reaction - Following the announcement of the financial results, KinderCare's stock price dropped by $3.92 per share, or 22.17%, closing at $13.76 per share on March 21, 2025 [4]